MK-608

維基百科,自由的百科全書
MK-608
臨床資料
其他名稱7-Deaza-2』-C-methyladenosine; 7DMA
法律規範狀態
法律規範
  • Investigational New Drug
識別資訊
  • (2R,3R,4R,5R)-2-(4-Aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
CAS號443642-29-3  checkY
PubChem CID
ChemSpider
UNII
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C12H16N4O4
摩爾質量280.28 g·mol−1
3D模型(JSmol英語JSmol
  • C[C@]1([C@@H]([C@H](O[C@H]1n2ccc3c2ncnc3N)CO)O)O
  • InChI=1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1
  • Key:IRZRJANZDIOOIF-GAJNKVMBSA-N

MK-608是一種抗病毒藥物,屬於腺苷類似物(一種核苷類似物英語nucleoside analog)。它最初由默克公司開發,用於治療丙型肝炎。雖然它在動物研究中取得了較好的結果,[1][2]但最終在臨床試驗中失敗。[3]後來,它被廣泛用於體外及動物的抗病毒研究,並顯示出對一系列病毒的活性,如骨痛熱症[4]蜱傳腦炎病毒英語tick-borne encephalitis virus[5]脊髓灰質炎病毒[6][7]以及寨卡病毒[8][9]

參考文獻[編輯]

  1. ^ Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrobial Agents and Chemotherapy. March 2009, 53 (3): 926–34. PMC 2650549可免費查閱. PMID 19075052. doi:10.1128/AAC.01032-08. 
  2. ^ Olsen DB, Davies ME, Handt L, Koeplinger K, Zhang NR, Ludmerer SW, et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrobial Agents and Chemotherapy. February 2011, 55 (2): 937–9. PMC 3028818可免費查閱. PMID 21115793. doi:10.1128/AAC.00990-10. 
  3. ^ Arnold JJ, Sharma SD, Feng JY, Ray AS, Smidansky ED, Kireeva ML, et al. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLOS Pathogens. 2012, 8 (11): e1003030. PMC 3499576可免費查閱. PMID 23166498. doi:10.1371/journal.ppat.1003030. 
  4. ^ Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. The Journal of Infectious Diseases. March 2007, 195 (5): 665–74. PMID 17262707. doi:10.1086/511310可免費查閱. 
  5. ^ Eyer L, Valdés JJ, Gil VA, Nencka R, Hřebabecký H, Šála M, et al. Nucleoside inhibitors of tick-borne encephalitis virus. Antimicrobial Agents and Chemotherapy. September 2015, 59 (9): 5483–93. PMC 4538560可免費查閱. PMID 26124166. doi:10.1128/AAC.00807-15. 
  6. ^ Goris N, De Palma A, Toussaint JF, Musch I, Neyts J, De Clercq K. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Research. March 2007, 73 (3): 161–8. PMID 17055073. doi:10.1016/j.antiviral.2006.09.007. 
  7. ^ Wu R, Smidansky ED, Oh HS, Takhampunya R, Padmanabhan R, Cameron CE, Peterson BR. Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses. Journal of Medicinal Chemistry. November 2010, 53 (22): 7958–66. PMC 2990348可免費查閱. PMID 20964406. doi:10.1021/jm100593s. 
  8. ^ Eyer L, Nencka R, Huvarová I, Palus M, Joao Alves M, Gould EA, et al. Nucleoside Inhibitors of Zika Virus. The Journal of Infectious Diseases. September 2016, 214 (5): 707–11. PMID 27234417. doi:10.1093/infdis/jiw226可免費查閱. 
  9. ^ Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J. The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLOS Neglected Tropical Diseases. May 2016, 10 (5): e0004695. PMC 4862633可免費查閱. PMID 27163257. doi:10.1371/journal.pntd.0004695.